The Cooper Cos., Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2166485019
USD
77.03
1.19 (1.57%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.77 M

Shareholding (Apr 2025)

FII

27.24%

Held by 353 FIIs

DII

26.85%

Held by 70 DIIs

Promoter

0.04%

How big is The Cooper Cos., Inc.?

22-Jun-2025

As of Jun 18, The Cooper Cos., Inc. has a market capitalization of $14.02 billion, with net sales of $3.99 billion and a net profit of $414.20 million over the last four quarters.

As of Jun 18, The Cooper Cos., Inc. has a market capitalization of 14,021.02 million, classifying it as a Mid Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 3,988.20 million, while the sum of consolidated net profit for the same period is 414.20 million.<BR><BR>As of Oct'24, the reporting period shows shareholder's funds at 8,083.40 million and total assets at 12,315.20 million.

Read More

What does The Cooper Cos., Inc. do?

22-Jun-2025

The Cooper Companies, Inc. is a global medical device company in the Pharmaceuticals & Biotechnology industry, with a market cap of approximately $14 billion and quarterly net sales of $1 billion. Key financial metrics include a P/E ratio of 36.00 and a return on equity of 5.00%.

Overview:<BR>The Cooper Companies, Inc. is a global medical device company operating in the Pharmaceuticals & Biotechnology industry, with a market cap in the mid-cap bracket.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,002 Million (Quarterly Results - Apr 2025)<BR>- Net Profit: 88 Million (Quarterly Results - Apr 2025)<BR>- Market cap: USD 14,021.02 Million (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 36.00<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.30<BR>- Return on Equity: 5.00%<BR>- Price to Book: 1.69<BR><BR>Contact Details:<BR>- Address: 6101 Bollinger Canyon Rd Ste 500, SAN RAMON CA: 94583-5177<BR>- Tel: ['1 925 4603600', '1 925 4603663']<BR>- Fax: 1 510 4603649<BR>- Website: https://www.coopercos.com/

Read More

Should I buy, sell or hold The Cooper Cos., Inc.?

22-Jun-2025

Who are in the management team of The Cooper Cos., Inc.?

22-Jun-2025

As of March 2022, The Cooper Cos., Inc. management team includes A. Thomas Bender (Independent Chairman), Albert White (President & CEO), Allan Rubenstein (Independent Vice Chairman), Robert Weiss, Colleen Jay, and William Kozy (all Independent Directors). They are responsible for the company's strategic direction and governance.

As of March 2022, the management team of The Cooper Cos., Inc. includes the following individuals:<BR><BR>- Mr. A. Thomas Bender, who serves as the Independent Chairman of the Board.<BR>- Mr. Albert White, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Allan Rubenstein, who holds the position of Independent Vice Chairman of the Board and Lead Director.<BR>- Mr. Robert Weiss, who is a Director.<BR>- Ms. Colleen Jay, who serves as an Independent Director.<BR>- Mr. William Kozy, who is also an Independent Director.<BR><BR>This team plays a crucial role in guiding the company's strategic direction and governance.

Read More

Is The Cooper Cos., Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, The Cooper Cos., Inc. is in a mildly bearish trend, with daily moving averages and weekly Bollinger Bands indicating bearishness, while the stock has significantly underperformed the S&P 500 with a year-to-date return of -23.74%.

As of 3 October 2025, the technical trend for The Cooper Cos., Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness and weekly Bollinger Bands also showing a mildly bearish trend. However, the MACD and KST on a weekly basis are mildly bullish, providing some counterbalance. The RSI shows no signal on both weekly and monthly time frames, indicating a lack of momentum. <BR><BR>In terms of performance, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -23.74% versus the S&P 500's 14.18%, and a one-year return of -33.81% compared to 17.82% for the index.

Read More

Is The Cooper Cos., Inc. overvalued or undervalued?

11-Nov-2025

As of November 7, 2025, The Cooper Cos., Inc. is considered expensive and overvalued with a P/E ratio of 36, a PEG ratio of 1.69, and a year-to-date return of -23.07%, underperforming the S&P 500's 14.40%.

As of 7 November 2025, the valuation grade for The Cooper Cos., Inc. has moved from very expensive to expensive, indicating a slight improvement in perceived value but still suggesting overvaluation. The company is considered overvalued based on its P/E ratio of 36, which is significantly higher than peers such as Hologic, Inc. with a P/E of 21.83 and Align Technology, Inc. at 20.46. Additionally, the EV to EBITDA ratio stands at 15.35, which is also elevated compared to the industry average.<BR><BR>The Cooper Cos., Inc. shows a PEG ratio of 1.69, further highlighting its expensive valuation relative to growth expectations. The return comparison reveals that the stock has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -23.07% compared to the S&P 500's 14.40%. This trend reinforces the notion that the stock is overvalued in the current market context.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Operating profit has grown by an annual rate 12.55% of over the last 5 years

 
2

Flat results in Jul 25

3

With ROCE of 7.05%, it has a expensive valuation with a 1.60 Enterprise value to Capital Employed

4

High Institutional Holdings at 100%

5

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 13,979 Million (Small Cap)

stock-summary
P/E

36.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.28

stock-summary
Return on Equity

4.88%

stock-summary
Price to Book

1.67

Revenue and Profits:
Net Sales:
1,060 Million
(Quarterly Results - Jul 2025)
Net Profit:
98 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
14.73%
0%
14.73%
6 Months
15.12%
0%
15.12%
1 Year
-25.42%
0%
-25.42%
2 Years
-9.66%
0%
-9.66%
3 Years
-76.1%
0%
-76.1%
4 Years
-80.33%
0%
-80.33%
5 Years
-77.21%
0%
-77.21%

The Cooper Cos., Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
10.63%
EBIT Growth (5y)
12.55%
EBIT to Interest (avg)
9.81
Debt to EBITDA (avg)
2.54
Net Debt to Equity (avg)
0.30
Sales to Capital Employed (avg)
0.36
Tax Ratio
34.26%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
5.85%
ROE (avg)
13.03%
Valuation key factors
Factor
Value
P/E Ratio
36
Industry P/E
Price to Book Value
1.78
EV to EBIT
22.72
EV to EBITDA
15.35
EV to Capital Employed
1.60
EV to Sales
4.32
PEG Ratio
1.69
Dividend Yield
NA
ROCE (Latest)
7.04%
ROE (Latest)
5.00%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Apr 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 132 Schemes (45.86%)

Foreign Institutions

Held by 353 Foreign Institutions (27.24%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jul'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jul 2025 is 5.79% vs 3.90% in Apr 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jul 2025 is 12.09% vs -15.92% in Apr 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jul'25",
        "Apr'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,060.30",
          "val2": "1,002.30",
          "chgp": "5.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "271.10",
          "val2": "277.40",
          "chgp": "-2.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "33.50",
          "val2": "33.30",
          "chgp": "0.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "98.30",
          "val2": "87.70",
          "chgp": "12.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "165.70%",
          "val2": "184.40%",
          "chgp": "-1.87%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Oct'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Oct 2024 is 8.41% vs 8.61% in Oct 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Oct 2024 is 33.34% vs -23.74% in Oct 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Oct'24",
        "Oct'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,895.40",
          "val2": "3,593.20",
          "chgp": "8.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,119.50",
          "val2": "909.00",
          "chgp": "23.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "59.30",
          "val2": "62.20",
          "chgp": "-4.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "31.80",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "392.30",
          "val2": "294.20",
          "chgp": "33.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "181.20%",
          "val2": "139.50%",
          "chgp": "4.17%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jul'25 - QoQstock-summary
Jul'25
Apr'25
Change(%)
Net Sales
1,060.30
1,002.30
5.79%
Operating Profit (PBDIT) excl Other Income
271.10
277.40
-2.27%
Interest
33.50
33.30
0.60%
Exceptional Items
0.00
0.00
Consolidate Net Profit
98.30
87.70
12.09%
Operating Profit Margin (Excl OI)
165.70%
184.40%
-1.87%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jul 2025 is 5.79% vs 3.90% in Apr 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jul 2025 is 12.09% vs -15.92% in Apr 2025

Annual Results Snapshot (Consolidated) - Oct'24stock-summary
Oct'24
Oct'23
Change(%)
Net Sales
3,895.40
3,593.20
8.41%
Operating Profit (PBDIT) excl Other Income
1,119.50
909.00
23.16%
Interest
59.30
62.20
-4.66%
Exceptional Items
0.00
31.80
-100.00%
Consolidate Net Profit
392.30
294.20
33.34%
Operating Profit Margin (Excl OI)
181.20%
139.50%
4.17%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Oct 2024 is 8.41% vs 8.61% in Oct 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Oct 2024 is 33.34% vs -23.74% in Oct 2023

stock-summaryCompany CV
About The Cooper Cos., Inc. stock-summary
stock-summary
The Cooper Cos., Inc.
Pharmaceuticals & Biotechnology
The Cooper Companies, Inc. is a global medical device company. The Company operates through two business units: CooperVision, Inc. and CooperSurgical, Inc. CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses. CooperVision services three primary regions: the Americas; Europe, the Middle East and Africa (EMEA), and Asia Pacific. CooperVision offers spherical, aspherical, toric, multifocal and toric multifocal lens products in various modalities. CooperVision's products are primarily manufactured at its facilities located in the United Kingdom, Puerto Rico, Hungary, Costa Rica and New York. CooperSurgical offers an array of products and services focused on advancing the health of families through a portfolio of products and services focusing on women's health, fertility and diagnostics.
Company Coordinates stock-summary
Company Details
6101 Bollinger Canyon Rd Ste 500 , SAN RAMON CA : 94583-5177
stock-summary
Tel: 1 925 46036001 925 4603663
stock-summary
Registrar Details